Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Major depressive subtypes and treatment response

M Fava1, L A Uebelacker, J E Alpert

  • 1Depression Research Program, Clinical Psychopharmacology, Unit, Massachusetts General Hospital, Boston 02114, USA.

Biological Psychiatry
|October 6, 1997
PubMed
Summary

Patients with non-anxious depression showed greater improvement with fluoxetine treatment compared to those with anxious depression. Melancholic depression showed slightly less improvement on one measure, but other subtypes had no significant impact on fluoxetine response.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Teens' perspectives on yoga as a treatment for stress and depression.

Complementary therapies in medicine·2021
Same author

The Global Task Force for Chronic Pain in People with HIV (PWH): Developing a research agenda in an emerging field.

AIDS care·2021
Same author

Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.

Journal of affective disorders·2019
Same author

Face and predictive validity of the ClockΔ19 mouse as an animal model for bipolar disorder: a systematic review.

Molecular psychiatry·2017
Same author

Corrigendum to "Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants" [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1].

Journal of affective disorders·2017
Same author

Increased illness burden in women with comorbid bipolar and premenstrual dysphoric disorder: data from 1 099 women from STEP-BD study.

Acta psychiatrica Scandinavica·2017

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Background:

  • Major Depressive Disorder (MDD) is a heterogeneous condition.
  • Identifying predictors of treatment response is crucial for personalized medicine.
  • Fluoxetine is a widely used selective serotonin reuptake inhibitor (SSRI) for MDD.

Purpose of the Study:

  • To examine the association between distinct depressive subtypes and treatment outcomes.
  • To evaluate the efficacy of fluoxetine in patients with various depression subtypes.
  • To identify patient characteristics that predict response to fluoxetine therapy.

Main Methods:

  • A cohort of 294 outpatients with MDD received 8 weeks of fluoxetine treatment (20 mg/day).
  • Treatment response was assessed using the Hamilton Depression Rating Scale (HDRS)-17, Clinical Global Impressions-Severity, and HDRS-8.

Related Experiment Videos

  • Depressive subtypes, including melancholic, atypical, hostile, anxious depression, double depression, and comorbid personality disorders, were evaluated.

    • Main Results:

    • Non-anxious depressives demonstrated significantly greater improvement than anxious depressives across all outcome measures.
    • Melancholic depression was associated with marginally less improvement on the HDRS-17.
    • Other assessed depressive subtypes (atypical, hostile, double depression, comorbid personality disorders) did not show significant associations with differential treatment outcomes.

    Conclusions:

    • The presence or absence of anxiety comorbidity is a significant factor influencing fluoxetine treatment response in major depressive disorder.
    • While melancholic features may indicate slightly reduced response on specific measures, anxiety comorbidity appears to be a more robust predictor of differential outcomes.
    • These findings suggest that tailoring treatment strategies based on the presence of anxiety may enhance therapeutic efficacy in MDD patients treated with fluoxetine.